References
- Oradell NJ. Physician's Desk Reference. Medical Economics Company, Inc. 1990; 44: 1827–1829
- Ellenhorn MJ, Barceloux DG. Medical Toxicology. Diagnosis and Treatment of Human Poisoning. Elsevier Science Publishing Company, Inc., New York 1988; 580–586
- Burkhart M, Kulig KW. The diagnostic utility of flumazenil (a benzodiazepine antagonist) in coma of unknown etiology. Ann Emerg Med 1990; 19: 319–321
- Amrein R, Leishman B, Bentzinger C, Roncari G. Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anesthesiology. Med Toxicol 1987; 2: 411–429
- Prischl F, Dormer A, Grimm G, Smetana R, Hruby K. Value of flumazenil in benzodiazepine self-poisoning. Med Toxicol 1988; 3: 334–339
- Al Arieff, Friedman EA. Coma following non-narcotic drug overdosage: Management of 208 patients. Am J Med Sci 1973; 266: 405–426
- Goodman LS, Gilman AG. The Pharmacologic Basis of Therapeutics. Macmillan Publishing Company, New York 1985; 350–354
- Barash PG, Cullen BF, Stoelting RK. Clinical Anesthesia. JB Lipp Company, Philadelphia 1989; 283
- Martini C, Lucacchini A, Hrelia S, Rossi CA. Central and peripheral-type benzodiazepine receptors. GABAergic Transmission and Anxiety, G Biggio, E Costa. Raven Press, New York 1986; 1–10
- Willette RN, Barcas PP, Krieger AJ, Sapru HN. Endogenous GABAergic mechanisms in the medulla and the regulation of blood pressure. J Pharmacol Exp Ther 1984; 230: 34–39
- Gillis RA, Yamada KA, Dimicco JA. Central gamma-aminobutyric acid involvement in blood pressure control. Fed Proc 1984; 43: 32–38
- Geller E, Chernilas J, Halpern P, Niv D, Miller HL. Hemodynamics following reversal of benzodiazepine sedation with Ro 15–1788 in cardiac patients. Anesthesiology 1986; 65: A49
- Bonetti EP, Pleri L, Cumun R. Benzodiazepine antagonist Ro 15–1788: neurologic and behavioral effects. Psychopharmacology (Berlin) 1982; 78: 8–18
- Moehler H, Burkard WP, Keller HH, Richards JG, Haefely W. Benzodiazepine antagonist Ro 15–1788: Binding characteristics and interaction with drug-induced changes in dopamine turnover and cerebellar CGMP levels. J Neurochem 1981; 37: 714–722
- Hunkeler W, Moehler H, Pleri L. Selective antagonists of benzodiazepines. Nature 1981; 290: 514–516
- File SE, Pellow S. Intrinsic actions of the benzodiazepine antagonist Ro 15–1788. Psychopharmacology 1986; 88: 1–11
- Darragh A, Lambe R, Kenny M, Brick I. Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15–1788. Eur J Clin Pharmacol 1983; 24: 569–570
- Darragh A, Lambe R, O'Boyle C, Kenny M, Brick I. Absence of central effects in man of the benzodiazepine antagonist Ro 15–1788. Psychopharmacology 1983; 80: 192–195
- Klotz U, Ziegler G, Reimann IW. Pharmacokinetics of the selective benzodiazepine antagonist Ro 15–1788 in man. Eur J Clin Pharmacol 1984; 27: 115–117